US Food and Drug Administration approves Novo Nordisk’s weight management drug Wegovy

DENMARK – Novo Nordisk, a Danish drug company that focuses on lifestyle related diseases, has finally received the US Food & Drug Administration (USFDA) approval of its weight management drug, Wegovy. The drug Wegovy (brand name for once-weekly semaglutide 2.4 mg injection in the US), was developed to be an adjunct to diet and exercise for chronic weight management in obese adults. Wegovy will be the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist   therapy approved for weight management for people living with obesity across the world. Approval was…

Read More

Diabetes tech market continues to witness an upward trend as more companies are coming up with new innovations

US – Despite the volatility of last year’s economy due to the corona virus pandemic, diabetes technology companies experienced tremendous success. Analysts have been bullish on the market as companies target new patient populations and major product launches have been planned for 2021 with clinicians approving of the same. Recent surveys of healthcare professionals projecting both the use of continuous glucose monitors and insulin pumps to jump in the coming years. While continuous glucose monitoring (CGMs) and insulin pumps are the primary devices in diabetes tech, the space is also…

Read More

Lilly’s tirzepatide tops list ahead of ozempic as treatment candidate for type 2 diabetes

US – In the just concluded phase 3 trials, the American pharmaceutical company, Eli Lilly have provided results that showed its investigational Gastric inhibitory polypeptide (GIP) and Glucagon-like peptide 1 (GLP-1) inhibitor tirzepatide is superior to Novo Nordisk’s ozempic. The SURPASS-2 study compared the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to Ozempic (semaglutide) 1 mg in adults with inadequately controlled type 2 diabetes, as an add-on to metformin, a prescription medication used to treat diabetes. All three doses of Lilly’s drug demonstrated superior HbA1C…

Read More